Evaluation of a pharmacist-managed hepatitis C care clinic

American Journal of Health-System Pharmacy

Volumn 64, Issue 6, 2007, Pages 632-634

  Smith, Jason P ^a,d   Dong, Mamie H ^b   Kaunitz, Jonathan D ^c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAVAHS   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ambulatory care; Antivirals; Clinical pharmacists; Combined therapy; Economics; Hematopoietic agents; Hepatitis C; Peginterferon alfa 2 a; Peginterferon alfa 2 b; Ribavirin; Toxicity

Indexed keywords

ANTIANEMIC AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; DIPHENHYDRAMINE; DOXEPIN; GROWTH FACTOR; HYPNOTIC AGENT; LORAZEPAM; MIRTAZAPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; SERTRALINE; TEMAZEPAM; THYROXINE; TRAZODONE;

ADULT; AMBULATORY CARE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CYTOPENIA; DEPRESSION; DRUG COST; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEALTH CARE COST; HEPATITIS C; HUMAN; HYPOTHYROIDISM; MALE; NEUTROPENIA; OUTPATIENT DEPARTMENT; PATIENT CARE; PHARMACIST; PILOT STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 33947587903     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060153     Document Type: Article

References (23)

1. Dominitz JA, Boyko EJ, Koepsell TD et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005; 41:88-96.
2. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology. 2006; 43:S207-20.
3. Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord. 2004; 4:7-17.
4. Roselle GA, Danko LH, Kralovic SM et al. National Hepatitis C Surveillance Day in the Veterans Health Administration of the Department of Veterans Affairs. Mil Med. 2002; 167:756-9.
5. Leigh JP, Bowlus CL, Leistikow BN et al. Costs of hepatitis C. Arch Intern Med. 2001; 161:2231-7.
6. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med. 2004; 71(suppl 3):S17-21.
7. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology. 2002; 36:S114-20.
8. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358:958-65.
9. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-82.
10. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123:1061-9.
11. Reynolds P, Brand C, Barnett IC et al. VA health care: improvements needed in hepatitis C disease management practices. www.gao.gov/cgi-bin/getrpt? GAO-03-136 (accessed 2007 Jan 17).
12. Kolor B. Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. Pharmacotherapy. 2005; 25:1230-41.
13. Department of Veterans Affairs. VA treatment recommendations for patients with chronic hepatitis C, version 5. Fed Practitioner. 2003; 20:1-33.
14. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002; 36:S3-20.
15. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349:825-32.
16. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol. 1999; 31(suppl 1):88-91.
17. Rowan PJ, Tabasi S, Abdul-Latif M et al. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol. 2004; 38:530-4.
18. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003; 124:1711-9.
19. Fried MW, Hadziyannis SJ. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis. 2004; 24(suppl 2):47-54.
20. Nguyen HA, Miller AI, Dieperink E et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol. 2002; 97:1813-20.
21. Moreno-Otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat. 2005; 12:10-9.
22. Cawthorne CH, Rudat KR, Burton MS et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol. 2002; 97:149-55.
23. Gujral H, Viscomi C, Collantes R. The role of physician extenders in managing patients with chronic hepatitis C. Cleve Clin J Med. 2004; 71(suppl 3):S33-7.